|Lower respiratory infections (or lung infections) is one of the leading causes of death in both developing and developed countries. Traditional administrations of antibiotics happen through oral or intravenous methods. These two methods in many causes are not effective for treatment of lower respiratory infections because drugs cannot reach infections sites in the airway surfaces. Furthermore, oral or intravenous medicines have problems with synergy of more than two antibiotics because different drugs have different behaviors. This means the drugs will arrive at the infections site at different times. This leads to compromised antimicrobial activity and potential development of antimicrobial resistance. There is a need for a new technology that allows for a more efficient way to deliver these antibiotics to the infected areas in the airways for treatment of deadly lung infections.
Researchers at Purdue University have developed a new technology that solves the compromised antimicrobial efficacy with traditional oral or intravenous administrations. This new technology incorporates two or more synergistic components into a single particle which allows for simultaneous delivery with high efficiency to the infection area in the lungs. This maximizes the antimicrobial activity and minimize resistance development. There is also reduced local toxicity because of this technology. The addition of one component will improve the delivery efficiency and stabilize the other component. This new technology could open the door for much better therapies for treatment of dangerous lung infections.
-Maximized antimicrobial activity
-Minimized antimicrobial resistance
-Reduced local toxicity
-Improved delivery efficiency
-Stabilized other component
Apr 26, 2019
Apr 26, 2018
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486